The Impact of Preprocedural Blood Pressure on Outcome After M-TEER: The Paradox or Something Else?

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Dec 9

PMID 39648949

Authors

Marijana Tadic

Leonhard Schneider

Nicoleta Nita

Dominik Felbel

Michael Paukovitsch

Mathias Groger

Mirjam Kessler

Wolfang Rottbauer

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to investigate the influence of systolic blood pressure (SBP) values on admission on the outcome of mitral transcatheter edge-to-edge repair (M-TEER).

Methodology: We included all patients who underwent interventional MV repair in our institution between January 2010 and October 2020. All data are obtained from the MiTra ULM registry. Based on SBP values measured on admission, all patients were divided into four groups: < 120, 120-129, 130-139, and ≥ 140 mmHg.

Results: Eight hundred and fifty-eight patients were included in this study. There were no major differences in demographic and clinical characteristics between the four observed groups. The patients with SBP on admission ≥ 140 mmHg had the lowest prevalence of functional MR and the highest LVEF. Higher SBP at admission (HR 0.74, 95% CI: 0.63-0.87) and preprocedural LVEF values (HR 0.99, 95% CI: 0.97-0.99) were predictors of lower 1-year mortality but did not impact 1-year hospitalization rate or MACE in the whole study population. When patients were separated into two groups according to the mechanisms of MR (functional and structural), the results showed that higher SBP on admission and better preprocedural LVEF were associated with significantly lower 1-year CV mortality in both groups of patients, with functional and structural MR. Higher SBP at admission was also associated with lower 1-year CV mortality (HR 0.73, 95% CI: 0.55-0.96) in patients with preserved ejection fraction (LVEF > 50%), but not with 1-year rehospitalization and MACE.

Conclusion: Higher SBP on admission (> 140 mmHg) is an independent predictor of a better 1-year outcome in patients treated with M-TEER. The effect of higher SBP on outcome after M-TEER should be further investigated.

References

Raphael C, Whinnett Z, Davies J, Fontana M, Ferenczi E, Manisty C . Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure. Heart. 2008; 95(1):56-62. DOI: 10.1136/hrt.2007.134973. View

Siegel R, Biner S, Rafique A, Rinaldi M, Lim S, Fail P . The acute hemodynamic effects of MitraClip therapy. J Am Coll Cardiol. 2011; 57(16):1658-65. DOI: 10.1016/j.jacc.2010.11.043. View

Baumgartner H, Falk V, Bax J, De Bonis M, Hamm C, Holm P . 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38(36):2739-2791. DOI: 10.1093/eurheartj/ehx391. View

Perl L, Kheifets M, Guido A, Agricola E, Denti P, Wild M . Acute Reduction in Left Ventricular Function Following Transcatheter Mitral Edge-to-Edge Repair. J Am Heart Assoc. 2023; 12(13):e029735. PMC: 10356102. DOI: 10.1161/JAHA.123.029735. View

Spargias K, Lim D, Makkar R, Kar S, Kipperman R, O Neill W . Three-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. Catheter Cardiovasc Interv. 2023; 102(1):145-154. DOI: 10.1002/ccd.30686. View

Demir O, Ruffo M, Godino C, Ancona M, Ancona F, Stella S . Mid-Term Clinical Outcomes Following Percutaneous Mitral Valve Edge-to-Edge Repair. J Invasive Cardiol. 2020; 32(12):E313-E320. DOI: 10.25270/jic/20.00121. View

Stone G, Abraham W, Lindenfeld J, Kar S, Grayburn P, Lim D . Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. N Engl J Med. 2023; 388(22):2037-2048. DOI: 10.1056/NEJMoa2300213. View

Gaemperli O, Moccetti M, Surder D, Biaggi P, Hurlimann D, Kretschmar O . Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart. 2011; 98(2):126-32. DOI: 10.1136/heartjnl-2011-300705. View

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J . 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021; 43(7):561-632. DOI: 10.1093/eurheartj/ehab395. View

10.

Orban M, Karam N, Lubos E, Kalbacher D, Braun D, Deseive S . Impact of Proportionality of Secondary Mitral Regurgitation on Outcome After Transcatheter Mitral Valve Repair. JACC Cardiovasc Imaging. 2020; 14(4):715-725. DOI: 10.1016/j.jcmg.2020.05.042. View

11.

Qadir I, Salick M, Perveen S, Sharif H . Mortality from isolated coronary bypass surgery: a comparison of the Society of Thoracic Surgeons and the EuroSCORE risk prediction algorithms. Interact Cardiovasc Thorac Surg. 2011; 14(3):258-62. PMC: 3290369. DOI: 10.1093/icvts/ivr072. View

12.

Paukovitsch M, Felbel D, Groeger M, Rottbauer W, Markovic S, Tadic M . Diabetes Mellitus in Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair-A Decade Experience in 1000+ Patients. J Clin Med. 2023; 12(10). PMC: 10219195. DOI: 10.3390/jcm12103502. View

13.

Keller K, Hobohm L, Geyer M, Kreidel F, Ostad M, Lavie C . Impact of obesity on adverse in-hospital outcomes in patients undergoing percutaneous mitral valve edge-to-edge repair using MitraClip® procedure - Results from the German nationwide inpatient sample. Nutr Metab Cardiovasc Dis. 2020; 30(8):1365-1374. DOI: 10.1016/j.numecd.2020.04.009. View

14.

Kar S, Feldman T, Qasim A, Trento A, Kapadia S, Pedersen W . Five-year outcomes of transcatheter reduction of significant mitral regurgitation in high-surgical-risk patients. Heart. 2018; 105(21):1622-1628. DOI: 10.1136/heartjnl-2017-312605. View

15.

Schneider L, Nicoleta N, Schepperle N, Paukovitsch M, Haide U, Feuerabendt S . Implications of concomitant obstructive or restrictive pulmonary diseases on functional and clinical results after MitraClip. Catheter Cardiovasc Interv. 2021; 98(7):E1000-E1006. DOI: 10.1002/ccd.29893. View

16.

Gaemperli O, Biaggi P, Gugelmann R, Osranek M, Schreuder J, Buhler I . Real-time left ventricular pressure-volume loops during percutaneous mitral valve repair with the MitraClip system. Circulation. 2013; 127(9):1018-27. DOI: 10.1161/CIRCULATIONAHA.112.135061. View